Study: NCT01088048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally twice daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide administered orally